References
- Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary Syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the european organisation for research and treatment of cancer. J Clin Oncol. 2011;29:2598–2607.
- Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010 Aug 5;116(5):767–771.
- Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015 Sep;47(9):1011–1019. Epub 2015 Jul 20.
- Narducci MG, Scala E, Bresin A, et al. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2006 Feb 1;107(3):1108–1115. Epub 2005 Oct 4.
- Song Q, Ji Q, Li Q. The role and mechanism of B-arrestin in cancer invasion and metastasis (review). Int J Mol Med. 2018 Feb;41(2):631–639.
- Caprini E, Diks SH, Den Dunnen WFA, et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 2009 Nov 1;69(21):8438–8446.
- Cristofoletti C, Bresin A, Picozza M, et al. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia. 2018 Dec 5. DOI:10.1038/s41375-018-0305-8.
- Fujii K, Page BDG, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015 Oct;29(3):586–597.